Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.
about
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cellsInfluence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expressionGemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trialsPhase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.Gemcitabine and platinum combinations in pancreatic cancer.Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study.Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapyRecent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cellsDose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patientsPancreatic cancer: the evolving role of systemic therapy.Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II studyOxaliplatin: a review of evolving concepts.Developments in the systemic therapy of pancreatic cancer.Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer.Recent advances in management of patients with platinum-refractory testicular germ cell tumors.A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell linesRole of platinum agents in the management of advanced pancreatic cancer.Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trialEfficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphomaA phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.Gemox: a widely useful therapy against solid tumors-review and personal experience.The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?
P2860
Q24653228-0788A9D4-5628-4F51-8458-8E5BE3AB320DQ28347115-F9369CF2-BE72-4106-AC0B-E899B0CBED14Q30318857-65A33B7E-C426-4670-A9F6-3F99EBAF4E1DQ33338535-600FF97C-28D7-4977-9F92-F38FF3A2671CQ33344048-07B9DA88-5472-4C4E-9EC8-8D4B12E6ADF7Q33358104-B1021888-5B11-4FC2-AD24-315254A19EC6Q33366782-E7DAF7AF-990B-437F-97BC-F2DB98A10FCDQ33371225-73307E1E-9DFF-4FA3-8A00-BC10350AFD58Q33373017-3D1A5593-2C03-4280-95A6-CE9DB4805495Q33383423-78B89629-0D65-4050-A266-9E08BE8707A5Q33395485-C135D754-2730-42CB-9985-DDED7CA2ED3FQ33397349-3DEC316B-94F2-46D6-B63A-FA3EE7FE8039Q33400294-B58E3536-D510-4B9F-9717-DF47070C59EDQ33403870-E2DFE87C-8B4D-467A-9C9F-999E866EB7F0Q33407440-95F885AC-8418-4EF8-BE58-2F7BC4D5A2BAQ33414059-03A5FB99-8F49-4CB1-BAE5-C3677AECD7D5Q33417019-F0E4C8E1-B55D-4851-9E9E-4CD28628BA67Q33632330-99DC504A-DFD8-4202-BAA9-9859312A3278Q33670961-AF9325E6-875A-4BDF-BABE-20AAE790C7BDQ34343973-08F60142-58E5-4C09-B023-53CA692FCDA6Q34515547-E1F84602-0CDA-43A7-9A00-9934D130EB19Q34564463-5A05822C-8EB7-4462-A37F-1BA752DBBA4DQ34569008-08BD4055-4A5E-4C99-96AA-D7FB101169D1Q35087326-A66413F1-DA2D-4229-B5F1-ACD4AE0112E1Q35237773-D0DCC964-0D4D-42EC-A591-C6C672F0FDC0Q35776091-CE3C07DF-110B-43B4-BF59-D6CAEAE80A53Q35858069-58B4C168-A8FD-4619-B49A-B2863269D7C6Q36389456-D3C8BA9B-BCBE-41D3-B5E5-54B903578EB1Q36695083-84114EDC-B9C9-4526-A9FB-531717B9C6F2Q36880024-4ABA371B-1DBE-468B-A091-225DA5F5D8EBQ36979302-3F0C1774-48DB-44BD-B4C1-33D7C01CC2E9Q37113732-245C2B8D-C71A-45FF-B1E1-F37E19122980Q37273186-41020A2D-4BD6-4AB7-8A00-A22E1BDD767BQ37301747-166F51DE-C567-4BB8-ADDE-093B51456ACBQ37376566-62A0CB66-7A5B-4E29-BD74-901F1C108B3AQ37639577-94FC1533-BA7E-4E23-8048-80AAEC80E5E3Q37814700-CEEC04B6-224E-46E9-AB5A-D7B6760CFC3EQ38097811-F1E0AB63-A8FC-4F05-9DF4-FED2DB745651Q38768797-3386FEDF-FD54-4C75-BBC6-AF1516661DE1Q39022032-C10E6CE3-CA12-4E26-A53B-0DF3237B7B19
P2860
Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Supraadditive effect of 2',2'- ...... in in human cancer cell lines.
@en
type
label
Supraadditive effect of 2',2'- ...... in in human cancer cell lines.
@en
prefLabel
Supraadditive effect of 2',2'- ...... in in human cancer cell lines.
@en
P2093
P356
P1476
Supraadditive effect of 2',2'- ...... tin in human cancer cell lines
@en
P2093
E Cvitkovic
J M Woynarowski
P2888
P304
P356
10.1007/S002800050955
P577
1999-01-01T00:00:00Z
P6179
1001803904